Zai Lab Secures China Approval for TIVDAK in Cervical Cancer
SHANGHAI, China & CAMBRIDGE, Massachusetts, USA – June 9, 2026 Zai Lab has received approval from China’s National Medical...
artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology NSCLC Oncology oncology innovation Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory compliance targeted therapy
SHANGHAI, China & CAMBRIDGE, Massachusetts, USA – June 9, 2026 Zai Lab has received approval from China’s National Medical...
COPENHAGEN, Denmark, May 26, 2026 Adcendo ApS has announced a new clinical collaboration and supply agreement with MSD (Merck...
Cambridge, United Kingdom – May 22, 2026 AstraZeneca and Daiichi Sankyo announced that the European Medicines Agency’s Committee for...
Foster City, California, USA – May 22, 2026 Gilead Sciences, Inc. announced the successful completion of its acquisition of...
Tokyo, Japan – May 22, 2026 Astellas Pharma Inc. announced that the European Medicines Agency’s Committee for Medicinal Products...
Cambridge, United Kingdom – May 22, 2026 AstraZeneca and Daiichi Sankyo announced that the U.S. Food and Drug Administration...
North Chicago, Ill., USA – May 21, 2026 AbbVie announced new oncology research findings ahead of the 2026 American...
PARIS, France, May 8, 2026 Waiv, the Paris-based artificial intelligence precision medicine company formerly known as Owkin Dx, announced...
SHANGHAI, April 23, 2026 Mabwell has announced the initiation of a Phase III clinical trial for its proprietary Nectin-4-targeting...
London, United Kingdom | April 13, 2026 GSK plc has announced positive clinical data from its Phase 1 BEHOLD-1...
